E77.1 Insurance Policy Changes

ICD-10 E77.1 is officially defined as "Defects in glycoprotein degradation." code E77.1 is referenced in 4 tracked payer policy changes from Aetna and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E77.1 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Genetic Diseases (CPB 0871, reviewed 2025-12-22)
Aetna considers allogeneic hematopoietic cell transplantation medically necessary for alpha-mannosidosis, childhood-onset adrenoleukodystrophy, Fanconi anemia under stated criteria, erythropoietic protoporphyria with severe hepatopathy, fucosidosis, globoid cell leukodystrophy (Krabbe disease), metachromatic leukodystrophy, mucolipidoses, mucopolysaccharidoses, and Wolman disease. It also considers allogeneic transplant medically necessary for children with infantile malignant osteopetrosis confirmed by bone biopsy and radiographic imaging who do not have irreversible neurologic impairment or multi-organ failure. Allogeneic transplant for Barakat syndrome, autologous transplant for infantile malignant osteopetrosis, mucopolysaccharidosis or childhood-onset adrenoleukodystrophy, and hematopoietic cell transplantation (autologous, allogeneic or cord blood) for hereditary corneal defects, Huntington's disease or TRNT1 enzyme deficiency are considered experimental, investigational or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Lysosomal Storage Disorder Treatments (CPB 0442, reviewed 2026-07-08)
Aetna's commercial policy for lysosomal storage disorder treatments covers each enzyme replacement drug for the diagnoses and criteria listed, including Fabry disease, Pompe disease, Gaucher disease, MPS I, II, IVA, VI and VII, CLN2, acid sphingomyelinase deficiency, lysosomal acid lipase deficiency and alpha-mannosidosis. Lumizyme and Pombiliti are medically necessary only for members who have a contraindication, intolerance or ineffective response to Nexviazyme, and VPRIV is medically necessary only for members who have a contraindication, intolerance or ineffective response to both Cerezyme and Elelyso. Continuation of therapy is covered only for members who are responding to therapy.
Aetna · Identified Aug 13, 2026Medium impact
Pediatric Intensive Feeding Programs (CPB 0809, reviewed 2025-12-11)
Aetna considers professional services for pediatric intensive feeding programs medically necessary for infants and children with complex feeding and swallowing disorders when an interdisciplinary team provides the care and every listed condition is met. Those conditions include behavior problems interfering with feeding, a documented diagnosis-specific treatment plan with estimated length of treatment, medical causes of failure to thrive treated without resolving the feeding problem, physician coordination and oversight, one of the listed feeding problems, and no response to initial treatment by a single discipline over a 2-month period. Other indications, such as childhood obesity and Prader-Willi syndrome, are considered experimental, investigational, or unproven, and electrical stimulation for swallowing or feeding disorders is also considered experimental, investigational, or unproven.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA08.147, Velmanase alfa (Lamzede)
Independence Blue Cross reissued MA08.147 on 05/28/2025 with no substantive changes to communicate the company's continuing coverage position for velmanase alfa-tycv (Lamzede) for non-CNS manifestations of alpha-mannosidosis in pediatric and adult patients age 3+. The policy remains unchanged from its original 03/11/2024 effective date, including all coverage criteria, continuation requirements, and dosing specifications.

Watch E77.1

Get one email when a payer policy names E77.1, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code E77.1?

There are 4 tracked policy changes affecting code E77.1, including updates from Aetna, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code E77.1?

Payers that have issued tracked updates for code E77.1 include: Aetna, Independence Blue Cross.

How do I get notified when code E77.1 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code E77.1. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code E77.1?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Genetic Diseases (CPB 0871, reviewed 2025-12-22)

Lysosomal Storage Disorder Treatments (CPB 0442, reviewed 2026-07-08)

Pediatric Intensive Feeding Programs (CPB 0809, reviewed 2025-12-11)

MA08.147, Velmanase alfa (Lamzede)

What insurance policy changes affect code E77.1?

Which payers have updated policy for code E77.1?

How do I get notified when code E77.1 policy changes?

Why do payers change policies for code E77.1?